ICU MEDICAL, INC. (NASDAQ:ICUI) Files An 8-K Completion of Acquisition or Disposition of Assets

9

ICU MEDICAL, INC. (NASDAQ:ICUI) Files An 8-K Completion of Acquisition or Disposition of Assets

Item 2.01 thereof the completion on February 3, 2017 of the
acquisition of Hospira Infusion Systems (“HIS”), Pfizer,
Inc.’s global infusion therapy business, for $275 million in
cash, 3.2 million shares of ICU stock and a potential $225
million Earnout.

This Amendment No. 1 on Form 8-K/A is being filed by the Company to
amend the Original Report on February 9, 2017 solely to provide
certain audited combined consolidated financial statements of HIS
as required by Item 9.01(a) of Form 8-K and the unaudited pro forma
consolidated financial information required by Item 9.01(b) of Form
8-K, which were excluded from the Original Report in reliance on
Items 9.01(a)(4) and 9.01(b)(2) of Form 8-K. Except as provided
herein, the disclosures made in the Original Report remain
unchanged.
Item 9.01. Financial Statements and Exhibits.
(a) Financial Statements of Business Acquired
Audited combined financial statements of HIS as of, October 2, 2016
and December 31, 2015 and for the period from January 1, 2016 to
October 2, 2016 and for the years ended December 31, 2015 and 2014
are filed as Exhibit 99.1, and incorporated herein by reference.
(b) Pro Forma Financial Information
Unaudited pro forma condensed consolidated financial information as
of and for the nine months ended September 30, 2016 and as of, and
for the year ended, December 31, 2015 are filed as Exhibit 99.2 to
this Form 8-K/A and are incorporated herein by reference.
(d) Exhibits
Exhibit No.
Description
23.1
Consent of KPMG
99.1
Audited Combined Financial Statements of Pfizer Infusion
Systems as of October 2, 2016 and December 31, 2015 and
for the period from January 1, 2016 to October 2, 2016
and for the years ended December 31, 2015 and 2014
99.2
Unaudited Pro Forma Condensed Combined Financial
Information as of, and for the nine months ended,
September 30, 2016, and for the year ended December 31,
2015


About ICU MEDICAL, INC. (NASDAQ:ICUI)

ICU Medical, Inc. is engaged in the development, manufacturing and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, closed system transfer devices (CSTD), needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems. It operates through the segment, which is engaged in the development, manufacturing and sale of medical technologies used in infusion therapy, critical care and oncology applications. Its Infusion Therapy products include MicroClave and MicroClave Clear, Neutron, NanoClave, Clave and SwabCap. Its Critical Care products include Hemodynamic Monitoring Systems, Closed Blood Sampling and Conservation Systems, and Other Critical Care Products and Accessories. Its Oncology products include ChemoLock CSTD and components, ChemoClave CSTD and components and Diana hazardous drug compounding system.

ICU MEDICAL, INC. (NASDAQ:ICUI) Recent Trading Information

ICU MEDICAL, INC. (NASDAQ:ICUI) closed its last trading session down -0.40 at 148.15 with 93,452 shares trading hands.

An ad to help with our costs